Abstract
Behçet’s disease (BD) is a rare form of vasculitis in North America. Like other rare diseases, there is no high-quality evidence for biologic use beyond case reports/series, and thus, therapy remains controversial. We report on the case of a patient who failed to respond to conventional therapy with colchicine and NSAIDs. She responded to steroids but failed to tolerate steroid tapers despite azathioprine, methotrexate, infliximab, and etanercept and required chronic prednisone up to 20 mg daily due to recurrent severe mucosal ulcers with fever, erythema nodosum (EN), and arthritis. She received cyclophosphamide for another indication but even then failed steroid taper. After three courses of rituximab, she showed marked clinical improvement and was able to reduce prednisone to 8 mg and to return to school and work. A review of disease mechanisms and clinical literature is presented for those facing challenging cases where evidence is limited.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ohno S et al (2004) Behçet's disease with refractory uveoretinitis. J Rheumatol 31(7):1362–1368
Arida A et al (2011) Anti-TNF agents for Behçet’s disease: analysis of published data on 369 patients. Semin Arthritis Rheum 41:61–7
Benitah NR, Sobrin L, Papaliodis GN (2011) The use of biologic agents in the treatment of ocular manifestations of Behcet's disease. Semin Ophthalmol 26(4–5):295–303
Marsh EA, Davies LM, Llewelyn JG (2012) How to recognise and treat peripheral nervous system vasculitis. Pract Neurol. doi:10.1136/practneurol-2012-000464
Takeuchi A, Kodama M, Takatsu M, Hashimoto T, Miyashita H (1989) Mononeuritis multiplex in incomplete Behçet’s disease a case report and the review of the literature. Clin Rheumatol 8:375–380
Sadreddini S (2008) Treatment of retinal vasculitis in Behçet's disease with rituximab. Mod Rheumatol 18:306–308
Davatchi F, Shams H, Rezaipoor M, Sadeghi-Abdollahi B, Shahram F, Nadji A et al (2010) Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study). Int J Rheum Dis 13:246–52
Yazici Y, Yazici H (2010) Behcet’s syndrome. Springer, London
Demirkesen C, Tüzüner N, Mat C, Senocak M, Büyükbabani N, Tüzün Y, Yazici H (2001) Clinicopathologic evaluation of nodular cutaneous lesions of Behçet syndrome. Am J Clin Pathol 116(3):341–6
Kikuchi H, Aramaki K, Hirohata S (2008) Effect of infliximab in progressive neuro-Behçet's syndrome. J Neurol Sci 272(1–2):99–105
Iwata S, Saito K, Yamaoka K, Tsujimura S, Nawata M, Hanami K, Tanaka Y (2010) Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease. Mod Rheumatol 21(2):184–91
Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S, Hamuryudan V, Yazici H (2005) Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. J Rheumatol 32(1):98–105
Miserocchi E, Pontikaki M, Modorati M, Gattinara M, Meroni PL, Gerloni V (2011) Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev 11:35–39
Saadouna D, Bodaghib B, Bienvenuc B, Wechslera B, Sened D, Trade S, Abadf S, Cacouba P, Kodjikiang L, Sève P (2013) Biotherapies in inflammatory ocular disorders: interferons, immunoglobulins, monoclonal antibodies. 12(7):774–783
Kose O (2012) Development of immunopathogenesis strategies to treat Behçet's disease. Pathol Res Int 2012, 261989. doi:10.1155/2012/261989, 7 pages
Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhao, B.H., Oswald, A.E. Improved clinical control of a challenging case of Behçet’s disease with rituximab therapy. Clin Rheumatol 33, 149–150 (2014). https://doi.org/10.1007/s10067-013-2433-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-013-2433-x